Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer
Randomized Phase III Trial Evaluating the Impact of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer
Sponsor: UNICANCER
Terminated
low recruitment
Other terminated trials from UNICANCER
Listed as NCT01363466, this PHASE3 trial focuses on Adenocarcinoma and Adenosquamous Carcinoma and remains terminated or withdrawn. Sponsored by UNICANCER, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
May 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aix-en-Provence, France , Amiens, France , Angers, France , Beauvais, France , Bordeaux, France , Bressuire, France , Brest, France , Créteil, France , Dijon, France , Fontainebleau, France and 15 more locations